Drug Trial Radar · NCT05922436
a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergency
Last checked: Nov 20, 2026Latest source record: Jun 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
378
Planned (sponsor's estimate)
Start
Jul 15, 2023
Primary completion
May 24, 2024
Study completion May 25, 2024
Sponsor
- Lead sponsor
- Qilu Pharmaceutical (Hainan) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 28, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Multicentre, Randomized, Double-blind, Parallel Design Phase III Study to Evaluate the efficacy and safety of QLG2071 Versus Cleviprex® in the Treatment of Hypertensive Emergency and Sub-emergency
Conditions
- Hypertensive Emergency
Interventions
QLG2071Drug
intravenous injection
Cleviprex®Drug
intravenous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- the percentage of patients who reach the target range (Systolic Blood Pressure decreased by ≥15% and ≤25% from baseline) within 30 minutes of administrationTime frame: Within 30 minutes of the initiation of the infusion
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.